Engineering KRAS mutation-specific affinity binders: A new frontier in cancer research

Highlights:

• Cancer involves significant genetic and proteomic changes, making the analysis of cellular transitions crucial.
• The KRAS gene, frequently mutated at glycine codon 12, is a key player in various cancers, including pancreatic, lung, and colon.
• Recent advancements have focused on the G12C mutation, but G12D and G12V mutations remain without targeted treatments.
• Our research develops KRAS mutant-specific binders through innovative immunization and screening techniques, targeting wild-type and multiple mutations (G12D, G12S, G12C, G12A, G12R, G12V).
• These binders are valuable for cancer pathway research, cell organization studies, prognosis, and therapy.
• Comprehensive evaluation of these tools is critical for their application in both laboratory and clinical settings.

Explore the Latest Advances in Cancer Research

Dive into our cutting-edge research presented at the 2024 AACR Annual Meeting. Our latest poster offers groundbreaking insights into the development of KRAS mutant-specific antibodies, a pivotal step in understanding and combating various cancers.

About the AACR Annual Meeting

The AACR Annual Meeting is a vital event for the cancer research community, bringing together scientists, clinicians, and advocates to share the latest breakthroughs. Covering a wide spectrum of cancer research, this meeting is an essential platform for advancing cancer science and medicine.

Key Takeaways

• G12 KRAS mutation drives key cancers.
• Epivolve pinpoints amino acid-specific KRAS antibodies.
• High-affinity antibody identified for KRAS G12D.
• IGT-0084 clone targets G12D KRAS, excludes others.
• Platform adaptable for varied genetic and protein modifications.